Multiple treatment options—topical therapies, oral drugs, phototherapy, and biologics—are available to treat psoriasis. In particular, the approval of biologics other than TNF–α inhibitors (Almirall’s Ilumetri, Biotech’s Stelara, Eli Lilly’s Taltz, Jansenn’s Tremfya, Leo Pharma’s Kyntheum, Novartis’s Cosentyx) in recent years has helped advance psoriasis treatment and further expand physicians’ treatment armamentarium, especially for moderate to severe disease.
Current Treatment: Physician Insights probes current and future use of topical agents, phototherapy, and systemic therapies in mild, moderate, and severe patients in EU5. It extensively probes use of approved biologics and includes patient share, line of therapy, drivers of treatment selection, and barriers to broader usage.It also looks into how psoriasis is being treated in the EU5 today, as well as the factors behind those treatment decisions.
Our new Current Treatment: Physician Insights offering provides deep insights, with real-world evidence wherever possible.
Markets covered: France, Germany, Italy, Spain, United Kingdom
Primary research: Survey of 251 dermatologists in the EU5 fielded in July 2020.
Key companies: AbbVie, Almirall, Amgen, Eli Lilly, Janssen, LEO Pharma, Novartis, Pfizer, UCB
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.